4-(苄氧基)-3-硝基苯甲酸 | 17903-89-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-(苄氧基)-3-硝基苯甲酸
• 中文别名: 3-硝基-4-苄氧基苯甲酸
• 英文名称: 4-benzyloxy-3-nitrobenzoic acid
• 英文别名: 3-nitro-4-phenylmethoxybenzoic acid
• CAS: 17903-89-8
• 化学式: C₁₄H₁₁NO₅
• mdl: MFCD03425435
• 分子量: 273.245
• InChiKey: ZPGYWCMZSUFFFM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  20
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.071
• 拓扑面积：
  92.4
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  4-(苄氧基)-3-硝基苯甲酸 在 吡啶 、 4-二甲氨基吡啶 、 tin(II) chloride dihdyrate 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 生成 (S)-4-(2-(4-(benzyloxy)-3-(methylsulfonamido)benzoyloxy)-2-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)ethyl)-3,5-dichloropyridine 1-oxide
  参考文献：
  名称：

  Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

  摘要：

  The first steps in the selection process of a new anti-inflammatory drug for the inhaled treatment of asthma and chronic obstructive pulmonary disease are herein described. A series of novel ester derivatives of 1-(3-(cyclopropylmethoxy)-4-(difluoromethoxy)phenyl)-2-(3,5-di-chloropyriclin-4-yl) ethanol have been synthesized and evaluated for inhibitory activity toward cAMP-specific phosphodiesterase-4 (PDE4). In particular, esters of variously substituted benzoic acids were extensively explored, and structural modification of the alcoholic and benzoic moieties were performed to maximize the inhibitory potency. Several compounds with high activity in cell-free and cell-based assays were obtained. Through the evaluation of opportune in vitro ADME properties, a potential candidate suitable for inhaled administration in respiratory diseases was identified and tested in an in vivo model of pulmonary inflammation, proving its efficacy.

  DOI：

  10.1021/jm401549m
• 作为产物：
  描述：

  4-羟基-3-硝基苯甲酸 在 potassium carbonate 、 potassium hydroxide 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 3.5h， 生成 4-(苄氧基)-3-硝基苯甲酸
  参考文献：
  名称：

  Discovery of novel benzbromarone analogs with improved pharmacokinetics and benign toxicity profiles as antihyperuricemic agents

  摘要：

  DOI：

  10.1016/j.ejmech.2022.114682

文献信息

• NOVEL LOW-MOLECULAR-COMPOUND FOR IMPROVING PRODUCTION, MAINTENANCE AND PROLIFERATION OF PLURIPOTENT STEM CELLS, COMPOSITION COMPRISING THE SAME, AND CULTURE METHOD
  申请人：KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY

  公开号：US20150159142A1

  公开（公告）日：2015-06-11

  According to the present invention, when the novel low-molecular-weight compound RSC-133 is added in a culture process for producing reprogrammed pluripotent stem cells from human differentiated cells, it can increase the efficiency of reprogramming and can significantly reduce the time required for the induction of reprogramming. Particularly, the novel compound RSC-133 can substitute for c-Myc acting as both a reprogramming factor and an oncogenic factor, and it can effectively increase the efficiency of reprogramming in both normal oxygen culture conditions and hypoxic culture conditions. In addition, RSC-133 can inhibit the induction of aging occurring in the reprogramming process, exhibits the effect of promoting cell proliferation, and induces epigenetic activation to improve culture conditions for induction of reprogramming. The present invention will contribute to optimizing a process of producing induced pluripotent stem cells from a small amount of patient-specific somatic cells obtained from various sources, and thus it will significantly improve a process of developing clinically applicable personalized stem cell therapy agents and new drugs and will facilitate the practical use of these agents and drugs. In addition, the novel low-molecular-weight compound RSC-133 can provide a cell culture medium effective for maintaining the undifferentiated state of human embryonic stem cells that are typical pluripotent stem cells. The medium composition containing RSC-133 can effectively induce the proliferation of human embryonic stem cells in an undifferentiated state and can be effectively used for the development of a system for culturing large amounts of embryonic stem cells.

  根据本发明，当在从人类分化细胞生产重编程的多能干细胞的文化过程中添加新型的低分子量化合物RSC-133时，它可以提高重编程的效率，并且可以显著减少诱导重编程所需的时间。特别是，新型化合物RSC-133可以替代作为重编程因子和致癌因子的c-Myc，并且可以在正常氧文化条件和无氧文化条件下有效地提高重编程的效率。此外，RSC-133可以抑制在重编程过程中发生的衰老诱导，表现出促进细胞增殖的效果，并诱导表观遗传激活以改善重编程诱导的培养条件。本发明将有助于优化从各种来源获得的患者特异性体细胞的小量生产诱导多能干细胞的过程，从而将显著改进开发临床应用的个人化干细胞治疗剂和新药的过程，并将促进这些剂和药物的实用化。另外，新型的低分子量化合物RSC-133可以提供一个有效的细胞培养介质，用于维持典型多能干细胞的人胚胎干细胞的不分化状态。含有RSC-133的培养基质可以有效诱导人胚胎干细胞在不分化状态的增殖，并且可以有效地用于大量胚胎干细胞培养系统的开发。
• Novel bicyclic sulfonamide derivatives which are L-CPT1 inhibitors
  申请人：Ackermann Jean

  公开号：US20070191603A1

  公开（公告）日：2007-08-16

  The invention is concerned with novel heterobicyclic derivatives of formula (I) wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , V, W, X and Y are as defined in the description and in the claims, as well as physiologically acceptable salts and esters thereof. These compounds inhibit L-CPT1 and can be used as medicaments.

  这项发明涉及公式（I）的新异双环衍生物，其中R1、R2、R3、R4、R5、R6、V、W、X和Y的定义如描述和索赔中所述，以及其生理上可接受的盐和酯。这些化合物抑制L-CPT1，可用作药物。
• BCL-2 INHIBITORS AND THEIR USE AS PHARMACEUTICALS
  申请人：PRELUDE THERAPEUTICS INCORPORATED

  公开号：US20210346405A1

  公开（公告）日：2021-11-11

  The disclosure is directed to, in part, to BCL-2 inhibitors, pharmaceutical compositions comprising the same, as well as methods of their use and preparation.

  该披露涉及部分BCL-2抑制剂，包括含有它们的药物组合物，以及它们的使用和制备方法。
• Synthesis and crystal structures of lanthanide 4-benzyloxy benzoates: Influence of electron-withdrawing and electron-donating groups on luminescent properties
  作者：Sarika Sivakumar、M. L. P. Reddy、Alan H. Cowley、Kalyan V. Vasudevan

  DOI：10.1039/b917256d

  日期：——

  properties. The new complexes have been characterized by a variety of spectroscopic techniques and two of the Tb3+ complexes [1 and 2] have been structurally authenticated by single-crystal X-ray diffraction. Compounds 1 and 2 crystallize in the monoclinic space group P21/n and their molecular structures consist of homodinuclear species that are bridged by two oxygen atoms from two benzoate ligands. In the

  三个新 4-苄氧基苯甲酸 衍生品[4-苄氧基苯甲酸 = HL1; 3-甲氧基-4-苄氧基苯甲酸 = HL2; 3-硝基-4-苄氧基苯甲酸 = HL3]已被用作支持六种镧系元素配位化合物的配体[Tb 3+= 1–3 ;欧盟3+= 4–6 ]，目的是测试电子释放（-OMe）或吸电子（-NO 2）取代基对光物理性质的影响。新的配合物已通过多种光谱技术进行了表征，并且两个Tb 3+配合物[ 1和2 ]已通过单晶X射线衍射进行了结构鉴定。化合物1和2在单斜空间群P2 1 / n中结晶，其分子结构由同核物质组成，它们被两个桥联氧 来自两个的原子 苯甲酸酯配体。在1的情况下，羧酸盐配体配位到中心Tb 3+双齿螯合和双齿桥接模式的离子。相比之下，在化合物2的情况下，观察到三种不同的配位模式（双齿螯合，双齿桥接和单齿配位）。检查1和2的堆积图表明存在一维分子阵列，该分子阵列通过分子间结合在一起氢键合相互作用
• Benzoxazolyl- and benzothiazolyloxazolidinones
  申请人：Bayer Aktiengesellschaft

  公开号：US05529998A1

  公开（公告）日：1996-06-25

  The invention relates to benzoxazolyl- and benzothiazolyloxazolidinones, processes for their preparation and their use as medicaments, in particular as antibacterial medicaments.

  本发明涉及苯并噁唑基和苯并噻唑基噁唑烷酮的制备方法及其作为药物的用途，特别是作为抗菌药物。